Patients consider side-effects of the KRAS G12C inhibitor to be more tolerable and to have less interference on their lives than those due to docetaxel 

Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care  

Activating EZH2 mutations may define a new subset of aggressive Ewing sarcomas that benefit from treatment with an EZH2 inhibitor  

Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib 

Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target 

Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer 

Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments 

CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies  

Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors 

Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone